Dr Louise Leong, ABPI Director of R&D Policy, comments on the Medical Research Council’s (MRC) review of the UK molecular pathology landscape.
Dr Louise Leong said:
“The ABPI has long called for the UK to be a leading player in the research, development and use of stratified medicines, including companion diagnostics. We are fully supportive of the priorities identified by the Medical Research Council in its Molecular Pathology review and look forward to contributing to the action plan to address the issues that have been raised. Our vision includes a health service equipped with the capabilities to appropriately value and use diagnostics, and a joined up research and development landscape with strong partnerships between NHS, industry and academia. We also need to see the linking up across the currently fragmented areas of clinical research and use, pathology, and industry, so that patients can ultimately benefit from access to existing and new treatments.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com